Literature DB >> 25151619

Pathogenic tau species drive a psychosis-like phenotype in a mouse model of Alzheimer's disease.

J Koppel1, H Jimenez2, M Azose3, C D'Abramo2, C Acker2, J Buthorn2, B S Greenwald2, J Lewis4, M Lesser2, Z Liu5, P Davies2.   

Abstract

Psychotic Alzheimer's disease (AD+P) is a rapidly progressive variant of AD associated with an increased burden of frontal tau pathology that affects up to 50% of those with AD, and is observed more commonly in females. To date, there are no safe and effective medication interventions with an indication for treatment in this condition, and there has been only very limited exploration of potential animal models for pre-clinical drug development. Pathogenic tau is over represented in the frontal cortex in AD+P, especially in females. In order to develop a candidate animal model of AD+P, we employed a tau mouse model with a heavy burden of frontal tau pathology, the rTg(tauP301L)4510 mouse, hereafter termed rTg4510. We explored deficits of prepulse inhibition of acoustic startle (PPI), a model of psychosis in rodents, and the correlation between pathogenic phospho-tau species associated with AD+P and PPI deficits in female mice. We found that female rTg4510 mice exhibit increasing PPI deficits relative to littermate controls from 4.5 to 5.5 months of age, and that these deficits are driven by insoluble fractions of the phospho-tau species pSer396/404, pSer202, and pThr231 found to be associated with human AD+P. This preliminary data suggests the utility of the rTg4510 mouse as a candidate disease model of human female AD+P. Further work expanded to include both genders and other behavioral outcome measures relevant to AD+P is necessary.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acoustic Startle; Alzheimer's disease; Prepulse inhibition; Psychosis; Tangle; Tau

Mesh:

Substances:

Year:  2014        PMID: 25151619     DOI: 10.1016/j.bbr.2014.08.030

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  9 in total

1.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

2.  Cornel Iridoid Glycoside Suppresses Hyperactivity Phenotype in rTg4510 Mice through Reducing Tau Pathology and Improving Synaptic Dysfunction.

Authors:  Deng-Lei Ma; Yi Luo; Rui Huang; Zi-Run Zhao; Li Zhang; Ya-Li Li; Qi Wang; Lin Li; Lan Zhang
Journal:  Curr Med Sci       Date:  2021-01-11

Review 3.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

4.  Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice.

Authors:  Josh M Krivinko; Susan L Erickson; Eric E Abrahamson; Zachary P Wills; Milos D Ikonomovic; Peter Penzes; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2017-02-16       Impact factor: 4.673

Review 5.  Optimal treatment of Alzheimer's disease psychosis: challenges and solutions.

Authors:  Jeremy Koppel; Blaine S Greenwald
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-24       Impact factor: 2.570

6.  Mouse Model of Neurological Complications Resulting from Encephalitic Alphavirus Infection.

Authors:  Shannon E Ronca; Jeanon Smith; Takaaki Koma; Magda M Miller; Nadezhda Yun; Kelly T Dineley; Slobodan Paessler
Journal:  Front Microbiol       Date:  2017-02-07       Impact factor: 5.640

7.  Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease.

Authors:  Cyril Bories; Dany Arsenault; Myriam Lemire; Cyntia Tremblay; Yves De Koninck; Frédéric Calon
Journal:  Aging (Albany NY)       Date:  2017-05-16       Impact factor: 5.682

8.  The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT- and rTg(P301L)4510 mouse models of Alzheimer's disease.

Authors:  Heidy Jimenez; Leslie Adrien; Adam Wolin; John Eun; Eric H Chang; Ethan S Burstein; Jesus Gomar; Peter Davies; Jeremy Koppel
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01

9.  Anandamide Effects in a Streptozotocin-Induced Alzheimer's Disease-Like Sporadic Dementia in Rats.

Authors:  Daniel Moreira-Silva; Daniel C Carrettiero; Adriele S A Oliveira; Samanta Rodrigues; Joyce Dos Santos-Lopes; Paula M Canas; Rodrigo A Cunha; Maria C Almeida; Tatiana L Ferreira
Journal:  Front Neurosci       Date:  2018-09-21       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.